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Abstract
The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor (EGFR)
is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests
superiority of the EGFR inhibitor (EGFRI) cetuximab plus radiotherapy compared to radiotherapy
alone in patients with squamous cell carcinoma of the head and neck. Although not documented in
a study population, several reports indicate a possible overlap between radiation dermatitis and the
EGFRI-induced skin rash. We here present a case of severe skin reaction secondary to the addition
of cetuximab to radiotherapy.
Findings
A 56-year-old woman with squamous cell cancer of the
head and neck received primary chemoradiation at our
institution. Due to thrombocytopenia, chemotherapy had
to be stopped early and was replaced by the EGFR inhibi-
tor cetuximab. In a close temporal relationship to the first
dose, exacerbation of a pre-existing grade 1 radiation ery-
thema occurred within the high-dose radiation portals.
Clinically, features of both the EGFRI-induced acne-like
rash and radiation dermatitis coexisted within the irradi-
ated fields. Combined EGFRI-radiotherapy was continued
under close clinical surveillance without worsening of the
skin reaction. The case presented here corresponds to sim-
ilar experience which is increasingly published. Clinicians
should be aware of the possibly severe cumulation of der-
matotoxic effects in this specific therapeutic setting.
Background
Contemporarily, there is increasing evidence supporting
the concomitant use of cetuximab, a monoclonal anti-
body against the epidermal growth factor receptor
(EGFR), in addition to high-dose radiotherapy in primary
treatment concepts of head and neck cancer [1]. In com-
parison to conventional chemotherapy, molecularly tar-
geted agents reveal lower haematological toxicity.
However, some specific side-effects such as allergic rashes
and skin reactions may limit the therapeutic use and com-
promise the individual patient's compliance [2].
With respect to skin reactions secondarily to the adminis-
tration of EGFR inhibitors (EGFRI), pruritic follicular
eruptions with either pustular or maculopapular appear-
ance are most common with an estimated occurrence in
>70% of patients [2-4]. Although acne-specific features
such as comedones or microbial superinfection are lack-
ing, the morphology is usually referred to as acneiform.
Correspondingly, the clinical symptomatic is acne-like
with a characteristic distribution in seborrhoeic areas
(face, V-shaped neckline, upper torso). Histopathological
analyses show enlargement of follicles with suppurative
folliculitis and follicular plugging by keratin as conse-
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quence of the altered keratinocyte differentiation and
increased apoptosis by the EGFR blockade [5].
Apparently, there is a great diversity of morphologic man-
ifestations, and the majority of patients will experience
only mild skin symptoms. However, severe reactions have
been described in up to 10% of patients (grade 3/4
according to the common toxicity criteria) [3,6,7]. There
is only few information available concerning possible risk
factors as well as interferences with other dermatotoxic
factors as, for example, concomitant radiotherapy.
Case presentation
We report on a 56-year-old woman suffering from a squa-
mous-cell carcinoma of the right base of tongue, 3 × 5 cm
in diameter. The patient declared alcohol abuse 10 years
ago, and had Child-Pugh class A liver cirrhosis. Computed
tomographic (CT) scanning of the whole body revealed a
stage IVA disease (cT2N2cM0). The patient was scheduled
for primary hyperfractionated accelerated chemoradiation
according to the German Cancer Society 95-06 schedule
[8]. Radiotherapy consisted of a three-dimensional con-
formal technique with a concomitant boost to the pri-
mary tumour and upper neck by lateral opposed portals
(72.0 Gy/45 fractions/42 days). 49.6 Gy in 29 fractions
were given to the cervical lymphatics and the lower ante-
rior neck.
In parallel to radiotherapy, systemic therapy with contin-
uous infusional 5-fluorouracil (600 mg m-2, days 1–5)
and mitomycin C (10 mg m-2, days 5 and 36) was started.
However, due to progressive grade 2 thrombocytopenia,
chemotherapy had to be stopped on day 4. In the progress
of radiotherapy, oral grade 2 mucositis developed in week
3, and the patient got a gastrostomy placed to ensure ade-
quate fluid and nutrition supply. To that time, the external
facial and cervical skin reaction consisted of a grade 1 dif-
fuse erythema without ulceration or epitheliolyses. The
patient's regular medications were morphine sulfate and
metamizole for pain relief; no other acne-inducing drugs
were used.
Due to the unforeseen stop of chemotherapy, a lack of
therapeutic efficacy was assumed and, therefore, parallel
treatment with cetuximab was offered according to the
published protocol [1]. After informed consent, the
patient received the first dose of cetuximab (250 mg m-2)
with a radiation dose of 44.0 Gy being applied. Within
hours after the first cetuximab infusion, vesicular and pus-
tular eruptions developed on both cheeks that evolved
into haemorrhagic lesions during the following days (Fig.
1). This cutaneous exacerbation was well confined to the
opposed lateral oropharyngeal portals (Fig. 2). In con-
trast, the lower cervical skin and neckline showed only a
minor erythema without ulceration or folliculitis. Hair or
nail changes were not reported.
The patient got an oral antihistamine for the relief of pru-
ritus, and a moisturising skin cream with antiseptic ingre-
dients was applied for topical treatment. Given the stable
development in the following, no other symptomatic
measures were taken. Laboratory findings were normal
without inflammatory changes. Herpes simplex (HSV-1)
Corresponding digitally reconstructed radiograph of the radi- ation portals Figure 2
Corresponding digitally reconstructed radiograph of the radi-
ation portals.
Exacerbated radiation dermatitis after cetuximab treatment Figure 1
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infection was ruled out by negative polymerase chain
reaction findings for HSV-1 DNA, performed out of vesic-
ular fluid as well as saliva smears. Serological tests for
HSV-1 antibodies revealed positive IgG titers, but were
negative for IgM.
The patient agreed to receive two further cetuximab infu-
sions on a weekly basis. The daily visit showed no worsen-
ing of the skin reaction. At the end of treatment, the
clinical findings were stable with clusters of confluent
haemorrhagic crusts on both cheeks.
At follow-up six weeks after completion of therapy, the
skin manifestations had declined to asymptomatic resid-
ual crusts in small areas. The patient proceeded to apply
regularly moisturising emollients. Another six weeks later,
intact dry skin had regenerated, but with hypopigmented
stains indicating the former necrotic lesions. Repeated CT
scanning at that time revealed a complete tumour
response.
Discussion
The skin rash by EGFRI is thought to be the direct conse-
quence of the EGFR blockade in basal epidermal keratino-
cytes as well as the outer root sheath of hair follicles,
leading to a local growth arrest and consecutive inflam-
mation. Its occurrence may be a pharmacodynamic
marker of the drug action and has been proposed as sur-
rogate parameter of tumour response [9,10].
EGFRI are increasingly used in parallel to, or, at least, in
short sequence to radiotherapy. For example, combined
treatment with cetuximab and radiotherapy has been
shown to improve locoregional control in patients with
squamous cell carcinoma of the head and neck in a phase
3 trial [1]. Whereas the administration of cetuximab led to
a significant amount of EGFRI-induced skin rashes in the
combined treatment group (8.2% vs. 0.5%, p < 0.001), no
statistically significant exacerbation of radiation dermati-
tis was reported (23 vs. 18% grade 3–5 reactions, p =
0.27).
In recent times, however, accumulating case reports reveal
grade 3/4 skin reactions within radiation fields in com-
bined treatment regimens [11-14]. The clinical localiza-
tion suggests a correlation with the radiation dose as well
as the former presence of intact pilosebaceous skin areas.
The underlying pathomechanism remains unclear, but a
synergistic inflammatory effect of both the cutaneous
EGFR blockade and radiation seems likely. Accordingly,
sparing of an EGFRI-induced rash has been reported in
areas of soft tissue fibrosis, where previous radiotherapy
has depleted skin glands and follicles [15].
The patient presented here developed ulcerative and
haemorrhagic dermatitis in a close temporal relationship
to the first application of cetuximab. Since we did not per-
form a skin biopsy, microscopic appearance and grading
of this reaction remain vague. However, the clinical
impression was comparable to those cases verified as
grade 4 epidermal necrosis by histological analysis [11].
Most recently, first consensus guidelines for the treatment
of cutaneous side-effects in combined EGFRI-radiother-
apy have been published [16]. Based on the grade of the
skin toxicity, treatment is adapted to the recommenda-
tions for EGFR-related rashes and radiation dermatitis. In
our patient, there was a stable development of the skin
reaction despite continuation of cetuximab therapy,
which corresponds to reports on spontaneous resolution
of skin rashes in EGFRI treatment alone [3]. However, this
may be an exceptional event. In general, clinicians should
be alert to the possibly severe skin toxicity after addition
of EGFRI to radiotherapy. For appropriate patients, a close
surveillance strategy may help to prevent further compli-
cations as well as an early treatment interruption.
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